[Electromyography in ophthalmological practice. II].

F. Fodor,B. Aşgian,A. Csiszar,I. Cheresteş

Abstract:

What problem does this paper attempt to address?

Analysis of the Dynamic Relationship Between Immune Profiles and the Clinical Features of Patients with COVID-19

Pingping Ren,Chaohong Zhu,Yongchun He,Hong Jiang,Jianghua Chen

DOI: https://doi.org/10.21037/atm-21-812

IF: 3.616

2021-01-01

Annals of Translational Medicine

Abstract:Background The novel coronavirus disease (COVID-19) has been declared a global pandemic, with the cumulative number of confirmed cases and deaths exceeding 150 million and 3 million, respectively. Here, we examined the dynamic changes in the immune and clinical features of patients with COVID-19. Methods Clinical data of 98 patients with confirmed COVID-19 diagnosis were acquired from electronic medical records and curated. The data were analyzed based on the stage of the admission, deterioration, and convalescence, which included age, sex, severity, disease stages, biochemical indicators, immune cells, inflammatory cytokines, and immunoglobulins. Additionally, temporal changes in the immune response in patients undergoing continuous renal replacement therapy (CRRT) were also examined. Results Compared to mild stage patients, severe stage patients with COVID-19 exhibited a significant reduction in lymphocyte [23.10 (17.58–33.55) vs. 4.80 (2.95–6.50), P<0.001], monocyte [8.65 (7.28–10.00) vs. 3.45 (2.53–4.58), P<0.001], and NK cell levels [244.00 (150.50–335.00) vs. 59.00 (40.00–101.00), P<0.001] but showed elevated levels of neutrophils [64.90 (56.30–73.70) vs. 90.95 (87.60–93.68), P<0.001], inflammatory cytokines [Interleukin-10, 3.05 (1.37–3.86) vs. 5.94 (3.84–8.35), P=0.001; and tumor necrosis factor-α, 11.50 (6.55–26.45) vs. 12.96 (12.22–36.80), P=0.029], which improved during convalescence. Besides, the number of immune cells—T lymphocytes, B lymphocytes, helper T cells, suppressor T cells, NK cells, and monocytes, except neutrophils—slowly increased in critically ill patients receiving CRRT from 0 to 3 weeks. Conclusions Our results indicate that the surveillance of immune cells may contribute to monitoring COVID-19 disease progression, and CRRT is a potential therapeutic strategy to regulate the immune balance in critically ill patients.
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19

Lucie Rodriguez,Pirkka T. Pekkarinen,Tadepally Lakshmikanth,Ziyang Tan,Camila Rosat Consiglio,Christian Pou,Yang Chen,Constantin Habimana Mugabo,Ngoc Anh Nguyen,Kirsten Nowlan,Tomas Strandin,Lev Levanov,Jaromir Mikes,Jun Wang,Anu Kantele,Jussi Hepojoki,Olli Vapalahti,Santtu Heinonen,Eliisa Kekalainen,Petter Brodin

DOI: https://doi.org/10.1016/j.xcrm.2020.100078

IF: 16.988

2020-01-01

Cell Reports Medicine

Abstract:Severe disease of SARS-CoV-2 is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5-7 days of stable disease. Efforts tomodulate this hyperinflammation and the associated acute respiratory distress syndrome rely on the unraveling of the immune cell interactions and cytokines that drive such responses. Given that every patient is captured at different stages of infection, longitudinal monitoring of the immune response is critical and systems-level analyses are required to capture cellular interactions. Here, we report on a systems-level blood immunomonitoring study of 37 adult patients diagnosed with COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. We describe an IFNg-eosinophil axis activated before lung hyperinflammation and changes in cell-cell co-regulation during different stages of the disease. We also map an immune trajectory during recovery that is shared among patients with severe COVID-19.
Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)

Xiaotian Dong,Mengyan Wang,Shuangchun Liu,Jiaqi Zhu,Yanping Xu,Hongcui Cao,Lanjuan Li

DOI: https://doi.org/10.14336/ad.2020.0317

2020-01-01

Aging and Disease

Abstract:Up to now, little is known about the detailed immune profiles of COVID-19 patients from admission to discharge. In this study we retrospectively reviewed the clinical and laboratory characteristics of 18 COVID-19 patients from January 30, 2020 to February 21, 2020. These patients were divided into two groups; group 1 had a severe acute respiratory syndrome coronavirus 2 nucleic acid-positive duration for more than 15 days (n = 6) and group 2 had a nucleic acid-positive duration for less than 15 days (n = 12). Group 1 patients had lower level of peripheral blood lymphocytes (0.40 vs. 0.78 ×109/L, p = 0.024) and serum potassium (3.36 vs. 3.79 mmol/L, p = 0.043) on admission but longer hospitalization days (23.17 vs. 15.75 days, p < 0.001) compared to Group 2 patients. Moreover, baseline level of lymphocytes (r = -0.62, p = 0.006) was negatively correlated with the nucleic acid-positive duration. Additionally, lymphocytes (420.83 vs. 1100.56 /μL), T cells (232.50 vs. 706.78 /μL), CD4+ T cells (114.67 vs. 410.44 /μL), and CD8+ T cells (94.83 vs. 257.44 /μL) in the peripheral blood analyzed by flow cytometry were significantly different between Group 1and Group 2. Furthermore, there was also a negative correlation between lymphocytes (r = -0.54, p = 0.038) or T cells (r = -0.55, p = 0.034) at diagnosis and the nucleic acid-positive duration, separately. In conclusion, the patients with nucleic acid-positive ≥ 15 days had significantly decreased lymphocytes, T cell and its subsets compared to those who remained positive for less than 15 days.
Modeling undesirable factors in efficiency evaluation

L. Seiford,Joe Zhu

DOI: https://doi.org/10.1016/S0377-2217(01)00293-4

IF: 6.4

2002-10-01

European Journal of Operational Research

Abstract:
The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes

Guoxing Tang,Min Huang,Ying Luo,Wei Liu,Qun Lin,Liyan Mao,Shiji Wu,Zhigang Xiong,Hongyan Hou,Ziyong Sun,Feng Wang

DOI: https://doi.org/10.3389/fimmu.2021.697622

IF: 7.3

2021-10-29

Frontiers in Immunology

Abstract:Objectives The longitudinal and systematic evaluation of immunity in coronavirus disease 2019 (COVID-19) patients is rarely reported. Methods Parameters involved in innate, adaptive, and humoral immunity were continuously monitored in COVID-19 patients from onset of illness until 45 days after symptom onset. Results This study enrolled 27 mild, 47 severe, and 46 deceased COVID-19 patients. Generally, deceased patients demonstrated a gradual increase of neutrophils and IL-6 but a decrease of lymphocytes and platelets after the onset of illness. Specifically, sustained low numbers of CD8 + T cells, NK cells, and dendritic cells were noted in deceased patients, while these cells gradually restored in mild and severe patients. Furthermore, deceased patients displayed a rapid increase of HLA-DR expression on CD4 + T cells in the early phase, but with a low level of overall CD45RO and HLA-DR expressions on CD4 + and CD8 + T cells, respectively. Notably, in the early phase, deceased patients showed a lower level of plasma cells and antigen-specific IgG, but higher expansion of CD16 + CD14 + proinflammatory monocytes and HLA-DR − CD14 + monocytic-myeloid-derived suppressor cells (M-MDSCs) than mild or severe patients. Among these immunological parameters, M-MDSCs showed the best performance in predicting COVID-19 mortality, when using a cutoff value of ≥10%. Cluster analysis found a typical immunological pattern in deceased patients on day 9 after onset, which was characterized as the increase of inflammatory markers (M-MDSCs, neutrophils, CD16 + CD14 + monocytes, and IL-6) but a decrease of host immunity markers. Conclusions This study systemically characterizes the kinetics of immunity of COVID-19, highlighting the importance of immunity in patient prognosis.

immunology
Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19

Zhifeng Deng,Minli Zhang,Ting Zhu,Niu Zhili,Zheming Liu,Rong Xiang,Wei Zhang,Yu Xu

DOI: https://doi.org/10.1016/j.ijid.2020.07.003

IF: 12.073

2020-09-01

International Journal of Infectious Diseases

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Introduction</h3><p>Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been widely spread. We aim to investigate the dynamic changes of peripheral blood lymphocytes subsets in adult patients with COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>Electronic medical records including demographics, clinical manifestation, comorbidities, laboratory data, and radiological materials of 435 hospitalized COVID-19 patients, with confirmed result of SARS-CoV-2 viral infection, were extracted and retrospectively analyzed. The counts of lymphocyte subsets at each week after the onset of the illness were compared with other weeks of illness and with those from normal individuals.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>The various lymphocyte subsets (CD3 +, CD4 +, CD8 +, CD19 +and CD16/56 +) were below the normal ranges at the first week after the onset of the illness, reaching a nadir during the second week, which increased gradually in the third week and returned to normal levels in the fifth week, but was still lower than the healthy controls. The CD3+, CD4+ and CD8+ counts were significantly lower in those with severe disease compared to those with non-severe disease, and in those patients that died compared to those who recovered.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Discussion</h3><p>our research indicates that the levels of peripheral blood lymphocyte subsets (CD3 +, CD4 +, and CD8 +) are associated with disease progression, severity, and prognosis in patients with COVID-19. Dynamic monitoring of human immune function is one of the indicators for evaluating the severity and prognosis of COVID-19 patients, and it is helpful to formulate appropriate treatment strategies.</p>

infectious diseases
Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Danrong Shi,Tianhao Weng,Jie Wu,Chunyan Dai,Rui Luo,Keda Chen,Miaojin Zhu,Xiangyun Lu,Linfang Cheng,Qiuqiang Chen,Fumin Liu,Zhigang Wu,Haibo Wu,Changzhong Jin,Miao Guo,Zhe Chen,Nanping Wu,Hangping Yao,Min Zheng

DOI: https://doi.org/10.3389/fimmu.2021.708184

IF: 7.3

2021-01-01

Frontiers in Immunology

Abstract:There is a worldwide pandemic of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; yet our understanding remains limited on the characteristic of antibodies, especially for dynamic long-term tracking. Sequential serum samples were collected up to 416 days post onset of symptoms (POS) from 102 patients who were hospitalized with coronavirus disease 2019 (COVID-19). Immunoglobulin (Ig)G, IgM, and IgA levels targeting SARS-CoV-2 spike 1 receptor-binding domain (S1-RBD), spike 2 extracellular domain (S2-ECD), and nucleocapsid protein (N) were quantified as well as neutralizing activity. We were pleasantly surprised to find that the antibody remained detective and effective for more than a year POS. We also found the varied reactions of different antibodies as time passed: N-IgA rose most rapidly in the early stage of infection, while S2-IgG was present at a high level in the long time of observation. This study described the long traceable antibody response of the COVID-19 and offered hints about targets to screen for postinfectious immunity and for vaccination development of SARS-CoV-2.
Analysis of Blood Index Characteristics in COVID-19 Patients and Their Associations with Different Outcomes

Xiaoping Xu,Shuqian Cai,Wei Chen,Huabin Wang,Junqi Wu

DOI: https://doi.org/10.1515/labmed-2020-0090

IF: 0.989

2021-01-01

Journal of Laboratory Medicine

Abstract:Abstract Objectives The clinical implications of different blood indices in patients with coronavirus disease-2019 (COVID-19) were analyzed at different stages. Methods We compared blood test results of 17 COVID-19 patients treated in Jinhua Central Hospital between January 1 and March 5, 2020 at different stages. We also compared the initial blood results of 17 COVID-19 patients with 115 influenza virus A/B (Flu A/B)-positive patients, 19 Mycoplasma pneumonia (MP)-positive patients and 50 healthy subjects (HSs). Results (1) The white blood cell count (WBC) and absolute neutrophil count (NEU#) were lower in the SARS-CoV-2 group than in the MP and Flu A/B groups; the eosinophil percentage (EO%) and absolute eosinophil count (EO#) were lower in the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) group than in the MP group (p<0.05). (2) Aspartate aminotransferase (AST) levels were significantly lower when patients were discharged from the hospital (p<0.05), EO% and EO# recovered at discharge, and returned to normal levels during follow-up (p<0.05). (3) When the throat swab was nucleic acid-negative but the stool was still positive, lymphocyte percentage (LY%) and absolute lymphocyte count (LY#) decreased (p<0.05). (4) As the cycle threshold (Ct) value of the nucleic acid increased or decreased, EO# showed a consistent trend. Conclusions Blood cell count indices upon hospital admission could be helpful to give some tips of diagnosis of SARS-CoV-2-infection, Flu A/B-infection and MP-infection; AST and EO# could be used to predict the outcome of patients. Feces turned negative for nucleic acid more slowly than throat swabs; LY# was lower during the fecal-positive period and low Ct values of fecal nucleic acid were negatively associated with the patient’s recovery level.
Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

Wen Wen,Wenru Su,Hao Tang,Wenqing Le,Xiaopeng Zhang,Yingfeng Zheng,Xiuxing Liu,Lihui Xie,Jianmin Li,Jinguo Ye,Liwei Dong,Xiuliang Cui,Yushan Miao,Depeng Wang,Jiantao Dong,Chuanle Xiao,Wei Chen,Hongyang Wang

DOI: https://doi.org/10.1038/s41421-020-0168-9

IF: 38.079

2020-05-04

Cell Discovery

Abstract:Abstract COVID-19, caused by SARS-CoV-2, has recently affected over 1,200,000 people and killed more than 60,000. The key immune cell subsets change and their states during the course of COVID-19 remain unclear. We sought to comprehensively characterize the transcriptional changes in peripheral blood mononuclear cells during the recovery stage of COVID-19 by single-cell RNA sequencing technique. It was found that T cells decreased remarkably, whereas monocytes increased in patients in the early recovery stage (ERS) of COVID-19. There was an increased ratio of classical CD14 ++ monocytes with high inflammatory gene expression as well as a greater abundance of CD14 ++ IL1β + monocytes in the ERS. CD4 + T cells and CD8 + T cells decreased significantly and expressed high levels of inflammatory genes in the ERS. Among the B cells, the plasma cells increased remarkably, whereas the naïve B cells decreased. Several novel B cell-receptor (BCR) changes were identified, such as IGHV3-23 and IGHV3-7, and isotypes (IGHV3-15, IGHV3-30, and IGKV3-11) previously used for virus vaccine development were confirmed. The strongest pairing frequencies, IGHV3-23-IGHJ4, indicated a monoclonal state associated with SARS-CoV-2 specificity, which had not been reported yet. Furthermore, integrated analysis predicted that IL-1β and M-CSF may be novel candidate target genes for inflammatory storm and that TNFSF13, IL-18, IL-2, and IL-4 may be beneficial for the recovery of COVID-19 patients. Our study provides the first evidence of an inflammatory immune signature in the ERS, suggesting COVID-19 patients are still vulnerable after hospital discharge. Identification of novel BCR signaling may lead to the development of vaccines and antibodies for the treatment of COVID-19.

cell biology
Dynamic Changes in Monocytes Subsets in COVID-19 Patients

Shuang Qin,Yujie Jiang,Xin Wei,Xiaoyuan Liu,Jingjing Guan,Yingxiao Chen,Hong Lu,Jingjing Qian,Zhongyong Wang,Xiangyang Lin

DOI: https://doi.org/10.1016/j.humimm.2020.12.010

IF: 2.211

2020-01-01

Human Immunology

Abstract:Background: Coronavirus disease 2019 (COVID-19) is affecting the whole world and threatening human health. We aim to investigate the immunological characteristics of monocytes in critical patients with COVID-19. Methods: The number and immune status of monocytes were detected by flow cytometry in 32 COVID19 patients and 18 healthy individuals. Results: In critical patients with COVID-19, the absolute number of total monocytes and CD16mono cyteswas significantly decreased but CD16' pro-inflammatory monocytes was increased compared to healthy controls. Antigen presentation potential of monocytes, as measured by HLA-DR expression, was suppressed, while their inflammatory phenotype (CD38 expression) was enhanced. Cytokine levels showed sustained increases in critical patients. And the levels of IL-6 were positively correlated with CD16' monocytes number. IL-6 and IL-10 levels were negatively correlated with HLA-DR expression of monocytes. During the recovery of COVID-19 patients, the count and immune status of monocyte subsets were restored by degrees. HLA-DR' monocytes possessed good sensitivity and specificity for predicting the incidence of critical patients with COVID-19. Conclusions: In critical patients with COVID-19, decline in number and HLA-DR expression of monocytes might lead to decreased antigen presentation potential and thus immunosuppression, while increased CD16' pro-inflammatory monocytes might mediate hyperinflammation. HLA-DR' monocytes might be a meaningful assisted indicator to predict the incidence of critical patients with COVID-19. (C) 2020 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.
A 3-Week Dynamic Differences of Immunological Parameters in Severe and Non-severe COVID-19

Qiang Li,Wei Xu,Weixia Li,Chenglu Huang,Chen Liang

DOI: https://doi.org/10.21203/rs.3.rs-36753/v1

2020-01-01

Abstract:Objective We aimed to compare the dynamic differences of immunological parameters in severe and non-severe COVID-19. Methods In this study, the cytokine profiles and lymphocyte subsets of 70 patients (31 severe COVID-19 and 39 non-severe COVID-19) were longitudinally analyzed. Results Compared with non-severe cases, severe cases had higher age (64 vs 36 years, p <0.001), more common comorbidities (74.2% vs 15.4%, p <0.001), and more frequently lymphopenia (0.7 vs 1.6×10 9 /L, p <0.001). Severe cases had markedly higher levels of IL-6, IL-8, and IL-10 than non-severe cases from baseline to 3 weeks after admission ( p <0.001). No significant differences were observed in the levels of IL-1β, IL-2, IL-4, IL-5, IL-12P70, IL-17, TNF-α, IFN-α, and IFN-γ between the two groups during the follow-up ( p > 0.05). The absolute numbers of CD3+, CD4+, CD8+, and CD45+ T cells were markedly lower in severe cases compared with that in non-severe cases from baseline to 3 weeks after admission ( p <0.001). The decrease of T lymphocyte subsets reached its peak from day 1 to 3 after admission, and gradually increased from day 4 to 21 in the non-severe group; however, reached its peak from day 4 to 7 after admission, and sustained at a low levels in the severe group. Conclusion The dynamic changes of cytokine profiles and T lymphocyte subsets are related with the disease severity of patients with COVID-19.
Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance

Diwenxin Zhou,Shuai Zhao,Keting He,Qiuhong Liu,Fen Zhang,Zhangya Pu,Lanlan Xiao,Lingjian Zhang,Shangci Chen,Xiaohan Qian,Xiaoxin Wu,Yangfan Shen,Ling Yu,Huafen Zhang,Jiandi Jin,Min Xu,Xiaoyan Wang,Danhua Zhu,Zhongyang Xie,Xiaowei Xu

DOI: https://doi.org/10.1186/s12879-024-09464-0

IF: 3.7

2024-06-09

BMC Infectious Diseases

Abstract:This study investigates the longitudinal dynamic changes in immune cells in COVID-19 patients over an extended period after recovery, as well as the interplay between immune cells and antibodies. Leveraging single-cell mass spectrometry, we selected six COVID-19 patients and four healthy controls, dissecting the evolving landscape within six months post-viral RNA clearance, alongside the levels of anti-spike protein antibodies. The T cell immunophenotype ascertained via single-cell mass spectrometry underwent validation through flow cytometry in 37 samples. Our findings illuminate that CD8 + T cells, gamma-delta (gd) T cells, and NK cells witnessed an increase, in contrast to the reduction observed in monocytes, B cells, and double-negative T (DNT) cells over time. The proportion of monocytes remained significantly elevated in COVID-19 patients compared to controls even after six-month. Subpopulation-wise, an upsurge manifested within various T effector memory subsets, CD45RA + T effector memory, gdT, and NK cells, whereas declines marked the populations of DNT, naive and memory B cells, and classical as well as non-classical monocytes. Noteworthy associations surfaced between DNT, gdT, CD4 + T, NK cells, and the anti-S antibody titer. This study reveals the changes in peripheral blood mononuclear cells of COVID-19 patients within 6 months after viral RNA clearance and sheds light on the interactions between immune cells and antibodies. The findings from this research contribute to a better understanding of immune transformations during the recovery from COVID-19 and offer guidance for protective measures against reinfection in the context of viral variants.

infectious diseases
The clinical course and its correlated immune status in COVID-19 pneumonia

Ruyuan He,Zilong Lu,Lin Zhang,Tao Fan,Rui Xiong,Xiaokang Shen,Haojie Feng,Heng Meng,Weichen Lin,Wenyang Jiang,Qing Geng

DOI: https://doi.org/10.1016/j.jcv.2020.104361

IF: 14.481

2020-06-01

Journal of Clinical Virology

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>To explore the clinical course and its dynamic features of immune status in COVID-19 patients and find predictors correlated with severity and prognosis of COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The electronic medical records of 204 patients with COVID-19 pneumonia confirmed by nucleic acid testing were retrospectively collected and analyzed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>All Patients were divided into severe (69) and non-severe group (135). Lymphocyte subsets count, including CD3 + T cell, CD4 + T cell, CD8 + T cell, B cell (CD19+) and NK cell (CD16 + 56+), were significantly lower in severe group (P<0.001). The dynamic levels of T lymphocytes in severe group were significantly lower from disease onset, but in the improved subgroup the value of T lymphocyte began to increase after about 15-day treatment and finally returned to the normal level. The cut-off value of the counts of CD3+ (576), CD4+ (391) and CD8+ (214) T cell were calculated and indicated significantly high sensitivity and specificity for severity of COVID-19.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>Our results shown that the decrease of CD3+, CD4+ and CD8 + T lymphocyte correlated with the course of patients with COVID-19 pneumonia, especially in severe cases. The level of T lymphocyte could be used as an indicator for prediction of severity and prognosis of patients with COVID-19 pneumonia. The application of glucocorticoid should be cautious in severe cases.</p>

virology
Controlled study to evaluate physical and psychosocial effects of a standardized in-patient rehabilitation program for patients after allogenic stem cell transplantation.

H. Bartsch,P. Auclair,A. Mumm,J. Weis

DOI: https://doi.org/10.1200/JCO.2006.24.18_SUPPL.16519

IF: 45.3

2006-06-20

Journal of Clinical Oncology

Abstract:16519 Background: Allogeneic stem cell transplantation (HSCT) involves somatic restrictions as well as psychosocial problems. We devolped a specific, standardized in-patient rehabilitation program (RP) for pts after HSCT. Main goals of this combined medical and psychosocial RP are the accelerated increase of physical strength and the decrease of psychosocial distress to improve health related quality of life (QoL).The purpose of this study was to evaluate this RP and define prognostic factors to discriminate between groups of pts. who might differentially benefit by the program. METHODS 132 pts. after HSCT were prospectively enrolled in the treatment group and compared to 22 pts. after HSCT who did not receive the specific RP. Besides an elucidated medical and physical assessment all pts. answered different standadized questionaires for evaluation of treatment related symptoms, fatigue (MFI), QoL (QlQ), and psycosocial distress (HADS). All measurements were repeated at different time points. RP-Pts received the first questionnaire at their admission to our center, controls during the first control after HSCT at their respective treatment center (T1). T2 was at discharge from the hospital or four to six weeks after T1. T3 was six months and T4 twelve months after T2. A matched-pairs strategy was chosen to compare the smaller group of 22 control patients with matching partners selected from the treatment group. RESULTS The analyses reveal that the rehabilitation patients as a group had significant poorer initial values compared to controls, particularly in physical parameters and fatigue. At T2 and T3 both groups did improve significantly compared to T1 in different physical and psychosocial measures. However the matched pair analysis is still ongoing and data will be presented. CONCLUSIONS Our data show that pts who are obviously more impaired following HSCT were preferentially transferred to our in-patient RP and benefit significantly from a standardized RP in physical as well as psychosocial conditions. The improvement increases over time and reaches after one year values comparable to those of healthy people. No significant financial relationships to disclose.
Immunological Evaluation on Potential Treatment Window for Hospitalized COVID-19 Patients

Jing Yuan,Shanglong Kou,Yanhua Liang,JianFeng Lan,Xiaohe Li,Lijiao Zeng,Rongrong Zou,Yingxia Liu,Lei Liu,Yanchao Pan

DOI: https://doi.org/10.2147/jir.s280331

IF: 4.5

2020-11-01

Journal of Inflammation Research

Abstract:PURPOSE: Novel coronavirus disease has become such an escalating epidemic that the exponential growth of infected patients has overloaded the health-care systems in many countries. Determination of early assessments for patients with a risk of clinical deterioration would benefit the management of COVID-19 outbreaks.PATIENTS AND METHODS: A total of 214 confirmed COVID-19 patients were enrolled from January 11th to February 11th 2020. Medical records including laboratory parameters, clinical outcomes and other characteristics of the admitted patients were analyzed retrospectively.RESULTS: The critical patients experienced a significantly prolonged onset-admission interval and presented with lymphopenia (<i>r</i>=-0.547, <i>p</i>=0.015) and lower albumin level (<i>p</i><0.001) 6 days after symptom onset. Early admission of critical patients significantly reduced the duration of hormone therapy. Starting from 9 days of hospital stay, the reduced lymphocyte counts exhibited linear growth. Furthermore, on days 9 and 12, significant correlations were demonstrated between immunological manifestations and duration of hormone therapy in critical patients, and length of hospital stay in severe patients. In addition, the virus negative conversion rate was more significantly correlated with increased lymphocytes in critical patients.CONCLUSION: Early intervention, within 6 days of symptom onset, benefited patients' recovery from critical illness. The 9-12 days of hospital care represented a valuable window during which to evaluate the therapeutic effects on physical recovery and virus clearance.

immunology
Dynamics of peripheral immune cells and their HLA‐G and receptor expressions in a patient suffering from critical COVID‐19 pneumonia to convalescence

Sheng Zhang,Jun Gan,Bao‐Guo Chen,Dan Zheng,Jian‐Gang Zhang,Rong‐Hai Lin,Yi‐Ping Zhou,Wei‐Ying Yang,Aifen Lin,Wei‐Hua Yan

DOI: https://doi.org/10.1002/cti2.1128

2020-01-01

Abstract:OBJECTIVES: Host immune responses are indispensable to combat the disease. We report the dynamics of peripheral immune cells, cytokines, and human leucocyte antigen-G (HLA-G) and its receptor expressions in a patient suffering from critical COVID-19 pneumonia to convalescence.METHODS: Clinical data of the patient were collected from medical records. The expressions of HLA-G and receptors ILT2, ILT4 and KIR2DL4 in peripheral immune cells were measured with flow cytometry.RESULTS: From critical COVID-19 to the convalescent stage, early lymphopenia was improved (median: 0.6 × 10<sup>9</sup> L<sup>-1</sup> vs. 0.9 × 10<sup>9</sup> L<sup>-1</sup>, <i>P</i> = 0.009), and an obvious fluctuation in WBC and neutrophil counts was observed. Initially, low levels of CD4<sup>+</sup> T cells (from 120 to 528 μL<sup>-1</sup>) and CD8<sup>+</sup> T cells (from 68 to 362 μL<sup>-1</sup>) gradually increased to normal levels. Meanwhile, high IL-6 (from 251.8 to 6.32 pg mL<sup>-1</sup>), IL-10 (from 39.53 to 5.21 pg mL<sup>-1</sup>) and IFN-γ (from 13.55 to 3.16 pg mL<sup>-1</sup>) levels decreased, and IL-4 (from 2.36 to 3.19 pg mL<sup>-1</sup>) and TNF-α (from 2.27 to 20.2 pg mL<sup>-1</sup>) levels increased quickly when the viral RNA returned negative. Moreover, the percentage of HLA-G<sup>+</sup> T cells, B cells and monocytes follows high-low-high pattern, while the percentage of receptors ILT2-, ILT4- and KIR2DL4-expressing cells remained relatively stable.CONCLUSION: Our findings provide valuable information on the dynamics of early peripheral immunological responses in SARS-CoV-2 infection. CD4<sup>+</sup> and CD8<sup>+</sup> T cells, cytokines and HLA-G<sup>+</sup> immune cells are associated with the natural history of the critical COVID-19 patient; however, future studies are necessary.

immunology
Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease

Mingyue Li,Weina Guo,Yalan Dong,Xiaobei Wang,Die Dai,Xingxing Liu,Yiquan Wu,Mengmeng Li,Wenjing Zhang,Haifeng Zhou,Zili Zhang,Lan Lin,Zhenyu Kang,Ting Yu,Chunxia Tian,Renjie Qin,Yang Gui,Feng Jiang,Heng Fan,Vigo Heissmeyer,Alexey Sarapultsev,Lin Wang,Shanshan Luo,Desheng Hu

DOI: https://doi.org/10.3389/fimmu.2020.580237

IF: 7.3

2020-10-14

Frontiers in Immunology

Abstract:Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) induced Coronavirus Disease 2019 (COVID-19) has posed a global threat to public health. The immune system is crucial in defending and eliminating the virus and infected cells. However, immune dysregulation may result in the rapid progression of COVID-19. Here, we evaluated the subsets, phenotypic and functional characteristics of natural killer (NK) and T cells in patients with COVID-19 and their associations with disease severity.Methods: Demographic and clinical data of COVID-19 patients enrolled in Wuhan Union Hospital from February 25 to February 27, 2020, were collected and analyzed. The phenotypic and functional characteristics of NK cells and T cells subsets in circulating blood and serum levels of cytokines were analyzed <i>via</i> flow cytometry. Then the LASSO logistic regression model was employed to predict risk factors for the severity of COVID-19.Results: The counts and percentages of NK cells, CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells and NKT cells were significantly reduced in patients with severe symptoms. The cytotoxic CD3<sup>-</sup>CD56<sup>dim</sup>CD16<sup>+</sup> cell population significantly decreased, while the CD3<sup>-</sup>CD56<sup>dim</sup>CD16<sup>-</sup> part significantly increased in severe COVID-19 patients. More importantly, elevated expression of regulatory molecules, such as CD244 and programmed death-1 (PD-1), on NK cells and T cells, as well as decreased serum cytotoxic effector molecules including perforin and granzyme A, were detected in patients with COVID-19. The serum IL-6, IL-10, and TNF-α were significantly increased in severe patients. Moreover, the CD3<sup>-</sup>CD56<sup>dim</sup>CD16<sup>-</sup> cells were screened out as an influential factor in severe cases by LASSO logistic regression.Conclusions: The functional exhaustion and other subset alteration of NK and T cells may contribute to the progression and improve the prognosis of COVID-19. Surveillance of lymphocyte subsets may in the future enable early screening for signs of critical illness and understanding the pathogenesis of this disease.

immunology
The dynamics of immune response in COVID‐19 patients with different illness severity

Bo Zhang,Daoyuan Yue,Yun Wang,Feng Wang,Shiji Wu,Hongyan Hou

DOI: https://doi.org/10.1002/jmv.26504

IF: 20.693

2020-10-10

Journal of Medical Virology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>This study aimed to analyze the dynamic changes of lymphocyte subsets and specific antibodies in coronavirus disease 2019 (COVID‐19) patients with different illness severity.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>The lymphocyte subsets and IgM and IgG antibody levels were retrospectively analyzed in 707 COVID‐19 cases.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The amounts of lymphocyte subsets were significantly decreased with the increased severity of illness and the levels of IgM and IgG were lower in critical cases than severe and moderate cases. In deceased patients, the lymphocytes subsets were significantly lower than recovered patients. However, the relationship between the levels of IgM and IgG and the amounts of lymphocyte subsets were not significantly correlated. During different stages of COVID‐19, the total T cell, CD4<sup>+</sup> T cell and CD8<sup>+</sup> T cell counts were gradually recovered to the normal levels in severe and critical groups but the change trend was relatively stable in moderate group. The production of IgM and IgG antibodies were delayed in critical groups but also could reach the peak levels at one month after illness onset and decreased to background levels. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>To detect the kinetics of lymphocytes and antibodies has important clinical value in predicting the illness severity and understanding the pathogenesis of COVID‐19.</p><p>This article is protected by copyright. All rights reserved.</p></section>

virology
The Dynamic Changes of Antibodies Against SARS-CoV-2 During the Infection and Recovery of COVID-19

Kening Li,Min Wu,Bin Huang,Aihua Zhong,Lü Li,Yun Cai,Lingxiang Wu,Mengyan Zhu,Jie Li,Ziyu Wang,Wei Wu,Wanlin Li,Bakwatanisa Bosco,Zhenhua Gan,Zhihua Wang,Qinghua Qiao,Jian Wu,Qianghu Wang,Shukui Wang,Xinyi Xia

DOI: https://doi.org/10.1101/2020.05.18.20105155

2020-01-01

Abstract:Deciphering the dynamic changes of antibodies against SARS-CoV-2 is essential for understanding the immune response in COVID-19 patients. By comprehensively analyzing the laboratory findings of 1,850 patients, we describe the dynamic changes of the total antibody, spike protein (S)-, receptor-binding domain (RBD)-, and nucleoprotein (N)- specific IgM and IgG levels during SARS-CoV-2 infection and recovery. Our results indicate that the S-, RBD-, and N- specific IgG generation of severe/critical COVID-19 patients is one week later than mild/moderate cases, while the levels of these antibodies are 1.5-fold higher in severe/critical patients during hospitalization (P<0.01). The decrease of these IgG levels indicates the poor outcome of severe/critical patients. The RBD- and S-specific IgG levels are 2-fold higher in virus-free patients (P<0.05). Notably, we found that the patients who got re-infected had a low level of protective antibody on discharge. Therefore, our evidence proves that the dynamic changes of antibodies could provide an important reference for diagnosis, monitoring, and treatment, and shed new light on the precise management of COVID-19.
Dynamic blood single-cell immune responses in patients with COVID-19

Lulin Huang,Yi Shi,Bo Gong,Li Jiang,Zhixin Zhang,Xiaoqi Liu,Jialiang Yang,Yongquan He,Zhilin Jiang,Ling Zhong,Juan Tang,Chunfang You,Qi Jiang,Bo Long,Tao Zeng,Mei Luo,Fanwei Zeng,Fanxin Zeng,Shuqiang Wang,Xingxiang Yang,Zhenglin Yang

DOI: https://doi.org/10.1038/s41392-021-00526-2

IF: 39.3

2021-03-06

Signal Transduction and Targeted Therapy

Abstract:Abstract The 2019 coronavirus disease (COVID-19) outbreak caused by the SARS-CoV-2 virus is an ongoing global health emergency. However, the virus’ pathogenesis remains unclear, and there is no cure for the disease. We investigated the dynamic changes of blood immune response in patients with COVID-19 at different stages by using 5’ gene expression, T cell receptor (TCR), and B cell receptors (BCR) V(D)J transcriptome analysis at a single-cell resolution. We obtained single-cell mRNA sequencing (scRNA-seq) data of 341,420 peripheral blood mononuclear cells (PBMCs) and 185,430 clonotypic T cells and 28,802 clonotypic B cells from 25 samples of 16 patients with COVID-19 for dynamic studies. In addition, we used three control samples. We found expansion of dendritic cells (DCs), CD14+ monocytes, and megakaryocytes progenitor cells (MP)/platelets and a reduction of naïve CD4+ T lymphocytes in patients with COVID-19, along with a significant decrease of CD8+ T lymphocytes, and natural killer cells (NKs) in patients in critical condition. The type I interferon (IFN-I), mitogen-activated protein kinase (MAPK), and ferroptosis pathways were activated while the disease was active, and recovered gradually after patient conditions improved. Consistent with this finding, the mRNA level of IFN-I signal-induced gene IFI27 was significantly increased in patients with COVID-19 compared with that of the controls in a validation cohort that included 38 patients and 35 controls. The concentration of interferon-α (IFN-α) in the serum of patients with COVID-19 increased significantly compared with that of the controls in an additional cohort of 215 patients with COVID-19 and 106 controls, further suggesting the important role of the IFN-I pathway in the immune response of COVID-19. TCR and BCR sequences analyses indicated that patients with COVID-19 developed specific immune responses against SARS-CoV-2 antigens. Our study reveals a dynamic landscape of human blood immune responses to SARS-CoV-2 infection, providing clues for therapeutic potentials in treating COVID-19.

biochemistry & molecular biology,cell biology

[Electromyography in ophthalmological practice. II].

Analysis of the Dynamic Relationship Between Immune Profiles and the Clinical Features of Patients with COVID-19

Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19

Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)

Modeling undesirable factors in efficiency evaluation

The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes

Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19

Dynamic Characteristic Analysis of Antibodies in Patients with COVID-19: A 13-Month Study

Analysis of Blood Index Characteristics in COVID-19 Patients and Their Associations with Different Outcomes

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

Dynamic Changes in Monocytes Subsets in COVID-19 Patients

A 3-Week Dynamic Differences of Immunological Parameters in Severe and Non-severe COVID-19

Longitudinal dynamic single-cell mass cytometry analysis of peripheral blood mononuclear cells in COVID-19 patients within 6 months after viral RNA clearance

The clinical course and its correlated immune status in COVID-19 pneumonia

Controlled study to evaluate physical and psychosocial effects of a standardized in-patient rehabilitation program for patients after allogenic stem cell transplantation.

Immunological Evaluation on Potential Treatment Window for Hospitalized COVID-19 Patients

Dynamics of peripheral immune cells and their HLA‐G and receptor expressions in a patient suffering from critical COVID‐19 pneumonia to convalescence

Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease

The dynamics of immune response in COVID‐19 patients with different illness severity

The Dynamic Changes of Antibodies Against SARS-CoV-2 During the Infection and Recovery of COVID-19

Dynamic blood single-cell immune responses in patients with COVID-19